Atom Therapeutics is touting data from a phase 2b/3 study as evidence that its gout drug has the efficacy and safety profile to stand out from the competition. | Atom Therapeutics is touting data from ...

Gout, a painful arthritis caused by uric acid buildup, triggers flare-ups worsened by genetics, diet, alcohol, or medication.

DelveInsight’s Chronic Gout Market Insights report includes a comprehensive understanding of current treatment practices, emerging chronic gout drugs, market share of individual therapies, and current ...

The FDA has accepted for review the BLA for nanoencapsulated sirolimus plus pegadricase in the treatment of uncontrolled gout.

WASHINGTON, DC — Use of sodium-glucose cotransporter-2 inhibitors (SGLT2i) reduced the need for urate-lowering therapy (ULT) and gout flare therapies in people who had both type 2 diabetes (T2D) and ...

A postdoctoral scholar in Gaucher's lab, Lais de Lima Balico, was the second co-author on the study. "Medications used to treat gout … are very effective when taken consistently, but adherence rates ...

The gout market is poised for steady growth, driven by the rising prevalence of the disease, increasing awareness, and the launch of novel therapies such as AR-882, Epaminurad, XNW3009, XRx-026, ...

Patients who use NSAIDs for paradoxical gout flare prevention when starting allopurinol demonstrate greater risk for adverse ...

Results of a confirmatory analysis using gout-related medications affirmed that prescription symmetry sequence analysis may be effective for identifying adverse drug events linked to a specific ...

Gout causes sudden flares of joint pain, which often arise during the nighttime, and in the big toe, though it may affect other joints including the ankles or knees. It is the most common type of ...

The chronic gout market is expected to maintain a stable growth over the forecast period (2025–2034). This growth is fueled by increasing prevalence due to aging populations and cardiometabolic ...